Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER AF-PCI
2012-001491-11Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib), stroke and systemic embolism (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinically significant bleeding. Started Feb 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)strokesystemic embolism
Beyond the preview
Go deeper on 2012-001491-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001491-11.